ArticleBMC genomics2022
High-throughput microarray reveals the epitranscriptome-wide landscape of m
Article in BMC genomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- The dual role of circHIPK3 in cancer and its implications for multiple drugs resistance: a systematic review and computational approach.Frontiers in oncology · 2025Pooled it
- Potential role of N6-methyladenosine modification in circular RNA biogenesis and function in the inflammatory responses.Frontiers in molecular medicine · 2025Review
- Competing endogenous RNAs network dysregulation in oral cancer: a multifaceted perspective on crosstalk and competition.Cancer cell international · 2024Review
- YTH domain family protein 3 accelerates non-small cell lung cancer immune evasion through targeting CD8Cell death discovery · 2024Article
- KIAA1429 promotes gastric cancer progression by destabilizing RASD1 mRNA in an mJournal of translational medicine · 2024Article
- METTL3-induced circ_0008345 contributes to the progression of colorectal cancer via the microRNA-182-5p/CYP1A2 pathway.BMC cancer · 2024Article
- circATAD2 mitigates CD8Cancer immunology, immunotherapy : CII · 2024Article
- The role of circular RNAs in regulating resistance to cancer immunotherapy: mechanisms and implications.Cell death & disease · 2024Review
- N6-methyladenosine methylation analysis of circRNAs in acquired middle ear cholesteatoma.Frontiers in genetics · 2024Article
- Non-coding RNA and drug resistance in head and neck cancer.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- New insights into the regulation of METTL3 and its role in tumors.Cell communication and signaling : CCS · 2023Review
- The roles of m6A methylation in cervical cancer: functions, molecular mechanisms, and clinical applications.Cell death & disease · 2023Review
- Comprehensive analysis of circRNAs for N7-methylguanosine methylation modification in human oral squamous cell carcinoma.FASEB bioAdvances · 2023Article
- mInternational journal of medical sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundEmerging transcriptome-wide high-throughput screenings reveal the landscape and functions of RNAs, such as circular RNAs (circRNAs), in human cancer. In addition, the post-transcriptional RNA internal modifications, especially N
resultsHere, we report an epitranscriptome-wide mapping of m
conclusionIn conclusion, our work preliminarily demonstrates the traits of m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.